Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK
- 31 August 2009
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (6), 671-680
- https://doi.org/10.1016/j.nucmedbio.2009.04.002
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Trastuzumab: triumphs and tribulationsOncogene, 2007
- Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptidesNature Protocols, 2007
- Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptideNuclear Medicine and Biology, 2007
- Reduced intestinal and renal amino acid transport in PDK1 hypomorphic miceThe FASEB Journal, 2006
- Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analoguesNuclear Medicine and Biology, 2006
- Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast CancerAnnals of Surgical Oncology, 2006
- In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fractionNuclear Medicine and Biology, 2006
- Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal AntibodyClinical Cancer Research, 2005
- N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with α-particle emitting 211AtNuclear Medicine and Biology, 2003
- Conjugation of Monoclonal Antibodies with TETA Using Activated Esters: Biological Comparison of64Cu-TETA-1A3 with64Cu-BAT-2IT-1A3Cancer Biotherapy & Radiopharmaceuticals, 2001